Zidovudine 300 mg
One of the first antiretroviral agents introduced into clinical practice, Zidovudine 300 mg Tablets are a nucleoside reverse transcriptase inhibitor used in combination regimens to manage HIV-1 infection under established treatment guidelines.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
300 mg twice daily, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 tablets
Zidovudine 300 mg
One of the first antiretroviral agents introduced into clinical practice, Zidovudine 300 mg Tablets are a nucleoside reverse transcriptase inhibitor used in combination regimens to manage HIV-1 infection under established treatment guidelines.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
300 mg twice daily, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 tablets
Zidovudine 300 mg
One of the first antiretroviral agents introduced into clinical practice, Zidovudine 300 mg Tablets are a nucleoside reverse transcriptase inhibitor used in combination regimens to manage HIV-1 infection under established treatment guidelines.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
300 mg twice daily, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 tablets